ioGlutamatergic Neurons in Drug Discovery

Accelerate your drug discovery workflows with reproducible, defined and easy-to-use cells

Human iPSC-derived ioGlutamatergic Neurons, part of our ioCells portfolio, have been reprogrammed using our precise reprogramming technology: opti-ox™ (optimised inducible over-expression). This next generation technology enables the precise reprogramming of entire cultures of stem cells into any cell type, consistently, on a vast scale. Overcoming the ultimate barriers in cell generation: cell definition and function, consistency and scalability.

Within days, human iPSCs convert into consistent, mature, functional excitatory neurons offering an alternative model for drug discovery. As a result timelines for target identification, phenotypic outputs and validation are enhanced. 

Key advantages

Consistent-orange-text_2

Batch to batch reproducibility and homogeneity create a stable human model for excitatory neuronal activity and disease.

Quick-orange-text

Cells are ready for experimentation within days showing mature neuronal properties within 2 weeks of induction.

Scalable-orange-text

Industrial scale quantities at a price point that allows the cells to be used from research to screening scale.

Easy-to-use-orange-text

Cells arrive programmed to rapidly mature upon revival. One medium required in a two-step protocol.

Discover the benefits of opti-ox powered ioGlutamatergic Neurons to accelerate target discovery, validation and screening. ioGlutamatergic Neurons are cryopreserved and arrive programmed to rapidly mature upon revival. With our simple protocol they form neuronal networks within days and have been assessed for use in multiple TC-plate formats (6 to 384-well plates). 

Robust drug screening at Charles River with ioGlutamatergic Neurons

Dr Marijn Vlaming | Head of Biology, Dr Mariangela Iovino | Group Leader and Dr Shushant Jain | Group Leader from Charles River touch upon one of the biggest challenges in developing drugs for CNS disorders - reproducibility. With ioGlutamatergic Neurons, the team explain how a 90 day experiment can be significantly shortened to approximately 10-14 days in a model that is physiologically relevant, robust and amenable for high throughput screening.

What our customers say about ioGlutamatergic Neurons

“Our major surprise when we first used the ioGlutamatergic Neurons was that after thawing the cells in 384-well format, we could see immediately after 2 days a nice neuronal network, and there was no well to well variability within the same plate. This made our assay quite robust.”

Dr Mariangela Iovino
Group Leader | Biology Discovery | Charles River

"These cells enable us to move rapidly as from the moment of plating within 4-7 days we have mature and functional neurons."

Dr Shushant Jain
Group Leader | In Vitro Biology | Charles River

“Making cells from iPSCs is a time-consuming activity and with the technology that bit.bio has developed it will become easier to generate different cell models.”

Dr Marijn Vlaming
Head of Biology - Beerse & Leiden | Charles River

”opti-ox leapfrogs my research.”

Dr Deepak Srivastava
Reader in Molecular Neuroscience | King's College London

    iodisease_models_logo-single_line-rgb

    Coming soon consistent, scalable and reliable isogenic disease models

    Huntington’s
    disease

    Parkinson’s
    disease

    Frontotemporal
    Dementia

    Amyotrophic
    lateral sclerosis

    Gaucher’s
    disease

    Duchenne
    muscular dystrophy

    ioDisease Models are a range of precision-engineered human iPSC-derived cells with disease-associated mutations for studying disease-driving mechanisms in CNS and muscle disease. 

    Using CRISPR/Cas-9 genome editing we have introduced disease-relevant mutations into opti-ox reprogrammed wild type ioCells. While the mutation drives the disease phenotype, the wild type cells serve as a genetically matched control. This isogenic pairing will help to detect even the most subtle phenotypic differences in complex disorders such as Duchenne muscular dystrophy, Huntington’s or Parkinson’s diseases.

    Contact us for early access and to find out about the launch of our ioDisease Models for neurodegenerative conditions including Huntington’s disease, Parkinson’s disease, Amyotrophic lateral sclerosis, Frontotemporal dementia and more.

    Download our Related Resources

    Related Products